Abbvie Endocrine Inc Drug Patent Portfolio
Abbvie Endocrine Inc owns 2 orange book drugs protected by 11 US patents Given below is the list of Abbvie Endocrine Inc's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8921326 | Sustained-release composition and method for producing the same | 05 Feb, 2031 | Active |
US9617303 | Sustained-release composition and method for producing the same | 22 Mar, 2028 | Active |
US8815801 | Controlled release composition and method of producing the same | 28 Jun, 2022 | Expired |
US6036976 | Sustained release microspheres and preparation thereof | 13 Dec, 2016 | Expired |
US7429559 | Controlled release composition and method of producing the same | 13 Dec, 2016 | Expired |
US5631020 | Method for producing microcapsule | 20 May, 2014 | Expired |
US5631021 | Method for producing microcapsule | 20 May, 2014 | Expired |
US5575987 | Method of producing sustained-release microcapsules | 02 Sep, 2013 | Expired |
US5716640 | Method of producing sustained-release microcapsules | 02 Sep, 2013 | Expired |
US5480656 | Prolonged release microcapsules | 02 Jan, 2013 | Expired |
US5643607 | Prolonged release microcapsules | 02 Jan, 2013 | Expired |
Latest Legal Activities on Abbvie Endocrine Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Abbvie Endocrine Inc.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 19 May, 2022 | US8921326 |
Payment of Maintenance Fee, 8th Year, Large Entity | 19 May, 2022 | US8921326 |
Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jan, 2022 | US8815801 |
Expire Patent
Critical
| 02 Nov, 2020 | US7429559 |
Payment of Maintenance Fee, 4th Year, Large Entity | 29 Sep, 2020 | US9617303 |
Maintenance Fee Reminder Mailed
Critical
| 18 May, 2020 | US7429559 |
Post Issue Communication - Certificate of Correction | 10 Sep, 2018 | US9617303 |
Payment of Maintenance Fee, 4th Year, Large Entity | 14 Jun, 2018 | US8921326 |
Payment of Maintenance Fee, 4th Year, Large Entity | 14 Jun, 2018 | US8921326 |
Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2018 | US8815801 |
Mail O.P. Petition Decision | 13 Jun, 2017 | US9617303 |
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 12 Jun, 2017 | US9617303 |
O.P. Petition Decision | 09 Jun, 2017 | US9617303 |
Adjustment of PTA Calculation by PTO | 09 Jun, 2017 | US9617303 |
Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 09 Jun, 2017 | US9617303 |
Abbvie Endocrine Inc Drug Patents' Oppositions Filed in EPO
Abbvie Endocrine Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 18, 2006, by Astellas B.V. Et Al.. This opposition was filed on patent number EP02738838A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP07859925A | Dec, 2020 | Instone Terry/ Read Howard Graham/Appleyard Lees IP LLP | Granted and Under Opposition |
EP02738838A | Feb, 2007 | QLT USA, Inc. | Patent maintained as amended |
EP02738838A | May, 2006 | MediGene Aktiengesellschaft | Patent maintained as amended |
EP02738838A | May, 2006 | Astellas B.V. et al. | Patent maintained as amended |
Abbvie Endocrine Inc's Family Patents
Abbvie Endocrine Inc Drug List
Given below is the complete list of Abbvie Endocrine Inc's drugs and the patents protecting them.
1. Lupron Depot
Lupron Depot is protected by 10 patents, out of which 9 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8921326 | Sustained-release composition and method for producing the same |
05 Feb, 2031
(6 years from now)
| Active |
US8815801 | Controlled release composition and method of producing the same |
28 Jun, 2022
(2 years ago)
| Expired |
US6036976 | Sustained release microspheres and preparation thereof |
13 Dec, 2016
(7 years ago)
| Expired |
US7429559 | Controlled release composition and method of producing the same |
13 Dec, 2016
(7 years ago)
| Expired |
US5631020 | Method for producing microcapsule |
20 May, 2014
(10 years ago)
| Expired |
US5631021 | Method for producing microcapsule |
20 May, 2014
(10 years ago)
| Expired |
US5575987 | Method of producing sustained-release microcapsules |
02 Sep, 2013
(11 years ago)
| Expired |
US5716640 | Method of producing sustained-release microcapsules |
02 Sep, 2013
(11 years ago)
| Expired |
US5480656 | Prolonged release microcapsules |
02 Jan, 2013
(11 years ago)
| Expired |
US5643607 | Prolonged release microcapsules |
02 Jan, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lupron Depot's drug page
2. Lupron Depot-ped Kit
Lupron Depot-ped Kit is protected by 9 patents, out of which 7 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8921326 | Sustained-release composition and method for producing the same |
05 Feb, 2031
(6 years from now)
| Active |
US9617303 | Sustained-release composition and method for producing the same |
22 Mar, 2028
(3 years from now)
| Active |
US6036976 | Sustained release microspheres and preparation thereof |
13 Dec, 2016
(7 years ago)
| Expired |
US5631020 | Method for producing microcapsule |
20 May, 2014
(10 years ago)
| Expired |
US6036976 | Sustained release microspheres and preparation thereof |
13 Dec, 2013
(10 years ago)
| Expired |
US5575987 | Method of producing sustained-release microcapsules |
02 Sep, 2013
(11 years ago)
| Expired |
US5716640 | Method of producing sustained-release microcapsules |
02 Sep, 2013
(11 years ago)
| Expired |
US5480656 | Prolonged release microcapsules |
02 Jan, 2013
(11 years ago)
| Expired |
US5643607 | Prolonged release microcapsules |
02 Jan, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lupron Depot-ped Kit's drug page